The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kartos Therapeutics
Leadership - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
Travel, Accommodations, Expenses - Kartos Therapeutics
KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy.
 
Michael K.K. Wong
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer; Pfizer/EMD Serono; Regeneron
 
Ciara Marie Kelly
Research Funding - AGIOS (Inst); Amgen (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst)
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Travel, Accommodations, Expenses - SpringWorks Therapeutics
(OPTIONAL) Uncompensated Relationships - Tricon Pharmaceuticals
 
Karl Lewis
Honoraria - Array BioPharma
Consulting or Advisory Role - Array BioPharma; Merck; Regeneron; Roche
Research Funding - Alkermes (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Alkermes; Genentech/Roche; Neon Therapeutics; Regeneron
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Regeneron
 
Jaspreet Singh Grewal
Employment - EMD Serono
Consulting or Advisory Role - Tempus
Research Funding - Bristol-Myers Squibb (Inst); Galera Therapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Regeneron (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - Adaptimmune (Inst); Alkermes (Inst); Astellas Pharma (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); GlycoNex (Inst); Immunocore (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Kura Oncology (Inst); Nektar (Inst); NGM Biopharmaceuticals (Inst); Oncoceutics (Inst); OncoSec (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Takeda (Inst); Targovax (Inst)
 
Jesse McGreivy
No Relationships to Disclose
 
Wayne Rothbaum
Stock and Other Ownership Interests - Acerta Pharma; Iovance Biotherapeutics; Kartos Therapeutics
Patents, Royalties, Other Intellectual Property - Acerta Pharma; Kartos Therapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Hope Qamoos
Employment - Kartos Therapeutics; Loxo
Stock and Other Ownership Interests - Kartos Therapeutics; Loxo
Travel, Accommodations, Expenses - Kartos Therapeutics; Loxo
 
James A. DeCaprio
Consulting or Advisory Role - EMD Serono; Merck
Research Funding - Constellation Pharmaceuticals (Inst)